Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hemispherx Biopharma Inc.

Division of HemispheRx Biopharma Inc.
www.hemispherx.net

Latest From Hemispherx Biopharma Inc.

Chronic Fatigue Syndrome Research Takes Leap Forward With NIH Funding

Research centers are collaborating on projects to find causes of disease; Ampligen, Rituxan and KPAX-002 are only drugs in clinical trials.

Research and Development Strategies Neurology

Pipeline Watch: Phase III Progress With Semaglutide, Sotagliflozin

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Deals Shaping the Medical Industry, September 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2016.

Deals BioPharmaceutical

Hemispherx 'Redoubling' US Efforts On Ampligen

Chronic fatigue drug received two FDA complete response letters, but company now agrees to additional study, new CEO says. Firm hopes Argentine approval also bodes well.

Research & Development Drug Approval Standards
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • HemispheRx Biopharma Inc.
  • Senior Management
  • Thomas Equels, Pres. & CEO
    Adam Pascale, CFO
    David R Strayer, MD, CSO & CMO
    Wayne Springate, SVP, Ops
  • Contact Info
  • Hemispherx Biopharma Inc.
    Phone: (215) 988-0080
    One Penn Ctr., 1617 JFK Blvd.
    Suite 500
    Philadelphia, PA 19103
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register